Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Eagan

Showing results (71-80 of 111) with videos related to

Pageof 12
Sort By:
American Journal of Clinical Oncology|June 1, 1986
Differing response rates and survival between squamous and non-squamous non-small cell lung cancer. Comparison of CAP versus MAPR T Eagan, S Frytak, E T Creagan, et al.
Cancer Treatment Reports|August 1, 1980
Phase II evaluation of the combination of triazinate, cyclophosphamide, doxorubicin, and cis-diamminedichloroplatinum(II) in patients with advanced adenocarcinoma of the lungR T Eagan, S Frytak, J N Ingle, et al.
Cancer Treatment Reports|May 1, 1981
Cyclophosphamide and VP-16-213 with or without cisplatin in squamous cell and small cell lung cancersR T Eagan, S Frytak, W C Nichols, et al.
American Journal of Clinical Oncology|April 1, 1987
No routine role for vincristine, adriamycin, and cyclophosphamide (VAC) or thoracic radiation therapy in extensive stage small cell lung cancerR T Eagan, S Frytak, R E Lee, et al.
Cancer Treatment Reports|September 1, 1979
Phase II study of cyclophosphamide, adriamycin, and cis-dichlorodiammineplatinum (II) by infusion in patients with adenocarcinoma and large cell carcinoma of the lungR T Eagan, S Frytak, E T Creagan, et al.
Journal of Neuro-Oncology|January 1, 1987
Comprehensive phase II evaluation of aziridinylbenzoquinone (AZQ, diaziquone) in recurrent human primary brain tumorsR T Eagan, R P Dinapoli, T L Cascino, et al.
Cancer Treatment Reports|September 1, 1976
A comparative clinical trial evaluating the combination of adriamycin, DTIC, and vincristine, the combination of actinomycin D, cyclophosphamide, and vincristine, and a single agent, methyl-CCNU, in advanced sarcomasE T Creagan, R G Hahn, D L Ahmann, et al.
Medical and Pediatric Oncology|January 1, 1978
A preliminary study of cyclophosphamide (NSC-26271), adriamycin (NSC-123127), imidazole carboxamide (NSC-45388), and actinomycin D (NSC-3053) with or without MER-BCG in patients with advanced sarcomasE T Creagan, J H Edmonson, R G Hahn, et al.
Oncology|January 1, 1981
Phase II studies of dianhydrogalactitol-based combination chemotherapy for recurrent brain tumorsR T Eagan, E T Creagan, H F Bisel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1994
Prophylactic cranial irradiation in complete responders with small-cell lung cancer: analysis of the Mayo Clinic and North Central Cancer Treatment Group data basesE G Shaw, J Q Su, R T Eagan, et al.
Pageof 12

Showing results (71-80 of 111) with videos related to

Sort By:
Pageof 12
American Journal of Clinical Oncology|June 1, 1986
Differing response rates and survival between squamous and non-squamous non-small cell lung cancer. Comparison of CAP versus MAPR T Eagan, S Frytak, E T Creagan, et al.
Cancer Treatment Reports|August 1, 1980
Phase II evaluation of the combination of triazinate, cyclophosphamide, doxorubicin, and cis-diamminedichloroplatinum(II) in patients with advanced adenocarcinoma of the lungR T Eagan, S Frytak, J N Ingle, et al.
Cancer Treatment Reports|May 1, 1981
Cyclophosphamide and VP-16-213 with or without cisplatin in squamous cell and small cell lung cancersR T Eagan, S Frytak, W C Nichols, et al.
American Journal of Clinical Oncology|April 1, 1987
No routine role for vincristine, adriamycin, and cyclophosphamide (VAC) or thoracic radiation therapy in extensive stage small cell lung cancerR T Eagan, S Frytak, R E Lee, et al.
Cancer Treatment Reports|September 1, 1979
Phase II study of cyclophosphamide, adriamycin, and cis-dichlorodiammineplatinum (II) by infusion in patients with adenocarcinoma and large cell carcinoma of the lungR T Eagan, S Frytak, E T Creagan, et al.
Journal of Neuro-Oncology|January 1, 1987
Comprehensive phase II evaluation of aziridinylbenzoquinone (AZQ, diaziquone) in recurrent human primary brain tumorsR T Eagan, R P Dinapoli, T L Cascino, et al.
Cancer Treatment Reports|September 1, 1976
A comparative clinical trial evaluating the combination of adriamycin, DTIC, and vincristine, the combination of actinomycin D, cyclophosphamide, and vincristine, and a single agent, methyl-CCNU, in advanced sarcomasE T Creagan, R G Hahn, D L Ahmann, et al.
Medical and Pediatric Oncology|January 1, 1978
A preliminary study of cyclophosphamide (NSC-26271), adriamycin (NSC-123127), imidazole carboxamide (NSC-45388), and actinomycin D (NSC-3053) with or without MER-BCG in patients with advanced sarcomasE T Creagan, J H Edmonson, R G Hahn, et al.
Oncology|January 1, 1981
Phase II studies of dianhydrogalactitol-based combination chemotherapy for recurrent brain tumorsR T Eagan, E T Creagan, H F Bisel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1994
Prophylactic cranial irradiation in complete responders with small-cell lung cancer: analysis of the Mayo Clinic and North Central Cancer Treatment Group data basesE G Shaw, J Q Su, R T Eagan, et al.
Pageof 12